News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Futura Medical "on track for a profit in 2025" after strong first half

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after the pharmaceutical company announced its interim results for the six months to 30 June 2023. Barder gives an overview of what he describes as a "pretty tremendous 2023 for Futura so far", highlighting the progress made in multiple markets with the company's topical erectile dysfunction treatment MED3000. He starts with a look at the enormously prospective US market where Futura secured both FDA approval for the product as well as a distribution deal with Haleon, who are responsible for the future launch and ongoing regulatory, development, marketing, and commercialisation of MED3000 in the USA. Barder also talks about the strides the company made in Europe during the first half and noted minimal complaints with over 200,000 packs sold. Financially, the company reported £1.7 million in revenue and a gross profit of £900,000, with Barder saying that he expects Futura to reach breakeven in 2024 and "is on track for a profit by 2025". Barder acknowledged the importance of production expansion to meet rising demand and highlighted efforts to strengthen distribution networks, particularly in Asia. Contact Details Proactive UK Ltd +44 20 7989 0813

September 18, 2023 11:20 AM Eastern Daylight Time

Article thumbnail News Release

September is Cholesterol Education Month


September is Cholesterol Education Month and for people with unsafe levels of high LDL (bad) cholesterol, there are many options in the treatment toolbox. Recently, Preventive Cardiologist Dr. Seth Baum participated in a nationwide satellite media tour to discuss high LDL cholesterol, best treatment options, and tips for patients navigating challenges with their health coverage. A video accompanying this announcement is available at: Heart disease remains the leading cause of death in the United States and LDL-cholesterol, what we call the “bad” cholesterol, is a major risk factor which can lead to a heart attack or a stroke. While many can lower their LDL cholesterol with a heart healthy diet, some will need medication to reach their Safe Zone. Statins are often the first-line of treatment for individuals with high LDL cholesterol, not all patients reach their recommended LDL cholesterol levels with statins alone. In these cases, lipid-lowering medications, known as PCSK9 inhibitors, are often recommended to help lower cholesterol levels. Unfortunately, individuals who are prescribed PCSK9 inhibitors are facing significant hurdles in accessing and using these potentially life-saving drugs, despite their proven efficacy in reducing LDL cholesterol. One major obstacle is insurance company denials or rejections. Data published in the November 2022 Journal of the American Medical Association found that for commercially insured patients prescribed a PCSK9 inhibitor, only 42% of initial rejections were overturned. Sadly, nearly 75% of patients rejected for a PCSK9 inhibitor ended up on no therapy, which is not a win for anyone. Research from the Family Heart Foundation shows that compared to individuals who were able to obtain their prescribed PCSK9 inhibitor, those whose prescription was rejected or abandoned experienced more heart attacks, strokes, and other cardiovascular events within 12 months. For more information and resources that can help, visit About Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC Dr. Seth J. Baum is Chief Scientific Officer at Flourish Research, and clinical affiliate professor of Cardiology at FAU Medical School. He actively consults in Clinical Lipidology and Cardiovascular Disease Prevention and continues to offer lipoprotein apheresis for patients in southeast and central Florida. Dr. Baum has practiced Preventive Cardiology and Clinical Lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. Dr. Baum is a past President of the American Society for Preventive Cardiology (ASPC). He currently serves on both the ASPC and Family Heart Foundation Advisory Boards. He has published over 100 peer reviewed papers and abstracts as well as two books. In 2013, he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019, Dr. Baum received Mended Hearts’ biennial Dwight Emary Harken Award. Dr. Baum is the Founder of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as Principal Investigator in over 100 clinical trials covering a broad range of disease states. Dr. Baum is the Chief Scientific Officer of Flourish Research, a leading national clinical research company. Dr. Baum is a graduate of Columbia College and Columbia College of Physicians and Surgeons, and completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology Contact Details YourUpdateTV +1 212-736-2727

September 18, 2023 10:27 AM Eastern Daylight Time

Article thumbnail News Release

Arecor Therapeutics expecting a busy end to the year after solid first half progress

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Thomas Warner from Proactive after the globally-focused biopharmaceutical group released its interim results for the six months to 30 June 2023. Howell gives an overview of recent progress, highlighting the initiation of the second Phase One clinical study for their concentrated rapid-acting insulin, with positive recruitment in type 2 diabetes patients. She also highlights fruitful partnerships, such as the one with Hikma, which obtained FDA confirmation for an accelerated regulatory pathway during the reporting period. Arecor's acquisition of Tetris Pharma led to successful commercialisation of their lead product, Ogluo, for severe hypoglycemia. Looking ahead, Arecor anticipates passing some significant milestones, including the launch of a biosimilar product and pivotal study progress for a partner's novel medicine. She says she's expecting "A busy end to the year and its really testament to the great work of Arecor and the team there and also the support from our shareholders and investors that we're very grateful for." Howell attributes the company's achievements to a dedicated team and supportive investors. Contact Details Proactive UK Ltd +44 20 7989 0813

September 18, 2023 09:13 AM Eastern Daylight Time

Article thumbnail News Release

M&L Healthcare's First MedTech Investment Receives FDA Approval Following Successful US Trials

M&L Healthcare

SINGAPORE - Media OutReach - 18 September 2023 - M&L Healthcare, in its first major MedTech investment, has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LimFlow System - a revolutionary therapy providing limb-saving treatment for patients with Chronic Limb-Threatening Ischemia (CLTI). The approval comes after successful outcomes in the PROMISE II Pivotal trial in the United States, recently published in the New England Journal of Medicine. The LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) is designed to re-establish blood flow in deep veins for "no-option" CLTI patients. It is the first and only FDA-approved device for TADV and provides no-option CLTI patients with access to a minimally invasive treatment. Type 2 diabetes is a major cause of CLTI, a condition that affects millions of people globally. The United States alone witnesses approximately 150,000 ischemic amputations each year, resulting in healthcare costs of over US$95 billion. LimFlow's therapy was developed to offer a limb-saving procedure to patients with incurable CLTI. The minimally invasive LimFlow is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins in CLTI patients who are facing major amputation and have exhausted all other therapeutic options. Given the high personal and social implications of amputation, as well as the alarming mortality rate of CLTI patients (approximately one in five amputees die within one year*), the availability of the LimFlow System marks a significant milestone. Dr. Steven Kum, Chief Medical Officer for M&L Healthcare, and a Vascular Surgeon, shared his thoughts on this achievement: "We are thrilled that the LimFlow System has received FDA approval for the LimFlow System this week. This breakthrough therapy has already achieved several significant milestones out of the work done in US, Europe and Singapore including the first-in-man procedure which was performed by the Vascular Team in Changi General Hospital Singapore. LimFlow has revolutionized the treatment of CLTI, aiding in wound healing and preventing debilitating amputations. It grants patients a second chance and potentially enhances their life span and quality of life. Considering Type 2 diabetes is the major cause of CLTI globally, the availability of LimFlow is crucial for improved patient outcomes." LimFlow overcame numerous hurdles, navigating the complexities of conducting clinical trials during the COVID-19 pandemic. Recognizing the significance of bringing this life-changing therapy to fruition, M&L Healthcare proactively provided the clinical support and necessary funds to mitigate the unexpected additional costs to ensure the clinical trial stayed on track. Reflecting on the achievement, Ms. Jocelyn Kum, Executive Director of M&L Healthcare, expressed her confidence in M&L Healthcare's capabilities as an investment partner, stating, "Our contribution to LimFlow's success is a testament to the dedication and business acumen that M&L Healthcare brings to the table." "Statistics show that only 1% of MedTech devices cleared for the US market in 2021 were novel and required pre-market approval, with the rest cleared via the 510(k) pathway. M&L recognized the early clinical and investment value of LimFlow and established itself as a reliable partner, demonstrating the financial stability and determination required to support investments throughout the challenging journey to success." [1] The LimFlow journey to date Established in Germany in September 2012, the LimFlow System was supported by Paris-based accelerator fund, MD Start I. By November 2012, LimFlow embarked on its first animal study under then-acting CEO, Mr. Tim Lenihan, a partner in MD Start I. MD Start approached Dr. Steven Kum and together with co-inventor Dr. Martin Rothman and CLTI expert Dr. Roberto Ferraresi, the team sought to develop a percutaneous procedure for Deep Venous Arterialization, leveraging their extensive clinical and engineering experience. Dr. Kum played a critical role in the development of the LimFlow technology and procedure, performing one of many cadaver studies in Singapore. In July 2014, he performed the first-in-human trial in Singapore with the purpose built Crossing Catheters and Valvulotome and subsequently completed a seven-patient pilot study with a 100% technical success rate. The results of the pilot study were promising with all primary safety endpoints met. 6 of 7 patients had avoided major amputations at 6 months and their wounds healed by an average of 4 months. In September 2014, LimFlow closed its Series A funding round, with M&L Healthcare as the lead investor. Now, a decade later, LimFlow stands apart as a game-changer in the field of medical technology. Having participated in all financing rounds since Series A, M&L Healthcare and Dr. Steven Kum have been integral to LimFlow's successful journey, pioneering a life-changing solution for CLTI. Unlike many medical devices which optimize existing solutions, LimFlow has addressed a significant, unmet need in CLTI, an area historically considered as a graveyard for technological advancements. What's Next for LimFlow In March 2023, a significant milestone was reached when LimFlow's US pivotal trial results were published in the New England Journal of Medicine. The six-month outcomes exhibited a limb salvage rate of 76% where over three-quarters of participants kept their leg, avoided amputation, and experienced progressive wound healing LimFlow previously received Breakthrough Designation from the FDA and the results substantially surpassed the FDA's performance target. This publication in the prestigious New England Journal of Medicine underscores the transformational potential of the LimFlow System for patients desperately in need. LimFlow successfully obtained Conformitè Europëenne (CE) Mark in October 2016 and is currently available commercially in Europe. FDA pre-market approval on 11 September2023. Building on these outstanding trial results and regulatory approvals in major markets, LimFlow is now gearing up for commercialisation in the US, the EU, and the UK, with plans for subsequent worldwide distribution. For more information about LimFlow, visit Patient testimonies Case study 1 Case study 2 Case study 3 [1] US FDA Premarket Approvals 2021 Updated 13 Jan 2022 US FDA 510(k) Approvals 2021 Updated 4 Jan 2022 About M&L Healthcare M&L Healthcare Investments is a wholly owned subsidiary of the Singapore-based Kum family, one of the pioneers in the Singapore shipping sector and a global investor in hospitality. Leveraging off over 40 years of business experience and entrepreneurial spirit spanning across several different sectors, M&L Healthcare aspires to be a leading life sciences company of the future. Led by Executive Director, Ms Jocelyn Kum, and Chief Medical officer, Dr Steven Kum, M&L Healthcare made its first investment in LimFlow Medical Technology in 2014. M&L Healthcare Investments has since participated in various financing rounds with investments in Europe, United States and Asia Pacific valued in excess of US$150 million. M&L Healthcare Investments is a subsidiary of the diversified M&L Group, which is valued at approximately US$2.5 billion. The group includes M&L Hospitality, M&L Shipping, and M&L Healthcare and Alternatives. With growing investments across various sectors, M&L Healthcare is poised to benefit from the group's extensive international network and strong investment acumen. This positions M&L Healthcare for significant growth. Contact Details M&L Healthcare Alina Morais

September 18, 2023 06:39 AM Eastern Daylight Time

Article thumbnail News Release

ACD/Labs Announce MilliporeSigma Partnership at SMASH 2023


The collaboration represents MilliporeSigma’s joint steps toward breakthrough innovation to make research and quality control in the lab more efficient and sustainable. The new ChemisTwin™ platform combines ACD/Labs’ industry-leading NMR predictors with Millipore Sigma’s digital reference materials (dRMs). ACD/Labs, an informatics company that develops and commercializes software in support of R&D, today announced a collaboration with MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company and one of the leading manufacturers/distributors of certified reference material world - wide. Through the first release version of its digital reference material (dRM) platform: ChemisTwin™, MilliporeSigma is providing scientists in quality control labs with an automated structure verification tool by NMR. This tool combines ACD/Labs’ industry-leading automated structure verification and prediction capabilities with Millipore Sigma’s expertise in high quality reference materials manufacturing. "With increasing demand for digital solutions in life sciences, we're proud to provide enabling technologies for MilliporeSigma’s digital reference material ChemisTwin™ platform,” said Andrew Anderson, Vice President of Informatics and Innovation Strategy at ACD/Labs. “Our partnership will empower scientists with a digital means for effective and robust structure verification.” “Our purpose is to shape the future of analytical testing, to make research and quality control in laboratories more efficient and sustainable. The launch of the ChemisTwin™ platform is a breakthrough innovation in our journey toward this objective, ultimately impacting life and health with science,” said Coralie Leonard, ChemisTwin™ project lead and Digital Business Model Developer, Analytical Chemistry at MilliporeSigma. "We have chosen to partner with ACD/Labs not only for their strong expertise in NMR spectral prediction and comparison, but also because they share our vision and passion to be a driver of industry change.” About ACD/Labs ACD/Labs is a leading provider of scientific software for R&D. We help customers in >94 countries around the world assemble digitized analytical, structural, and molecular information for effective decision-making, problem solving, and product lifecycle control. Our enterprise technologies enable automation of molecular characterization and facilitate chemically intelligent knowledge management. ACD/Labs provides worldwide sales and support and brings decades of experience and success helping organizations innovate and create efficiencies in their workflows. For more information, please visit Follow us on Twitter and LinkedIn. About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn. All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. Contact Details ACD/Labs Sanji Bhal +1 416-368-3435 Allison Matthews Company Website

September 18, 2023 03:00 AM Eastern Daylight Time

Article thumbnail News Release

Neural Therapeutics looks to history to solve today’s pharmaceutical problems

Neural Therapeutics Inc.

Neural Therapeutics CEO Ian Campbell joined Steve Darling from Proactive to shed light on the company's fascinating journey into the realm of plant-based active substances. Neural Therapeutics is a pioneering company with a unique focus: the development of over-the-counter dietary supplements and therapeutic medicines with a foundation in psychedelic-based treatments, particularly those derived from mescaline-containing cacti. Campbell explained that Neural Therapeutics has taken significant steps in establishing a supply chain in Peru, specifically for sourcing various species of mescaline-containing cacti, including the San Pedro cactus. To support its research initiatives, the company has diligently pursued and obtained the necessary permits from the National Service for Forest and Wildlife in Peru to collect wild species of cacti. These efforts signify a commitment to harnessing the potential of these plants to develop innovative solutions. Neural Therapeutics is strategically positioned to tap into today's burgeoning Nutraceutical and Pharmaceutical markets. By drawing from the rich traditions of utilizing natural substances, particularly those with a history of indigenous use, the company aims to bridge the past with modern science and healthcare. Contact Details Proactive Investors +1 604-688-8158

September 15, 2023 01:19 PM Eastern Daylight Time

Article thumbnail News Release

Valeo Pharma hits 7th straight consecutive quarter of revenue growth

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Proactive's Steve Darling to share news regarding the company's strong third-quarter performance. The company has once again shattered its own records, demonstrating remarkable growth in various key areas of its business. In 3Q 2023, the company achieved a milestone with record quarterly revenues reaching an impressive $14.1 million, a 132% increase when compared to the $6.1 million generated in the same period of the previous year. Notably, Valeo Pharma's two flagship products for managing asthma, Enerzair and Atectura, were instrumental in driving this growth, with a 234% increase in sales. Adjusted gross profit soared to $5.1 million, marking a 106% rise from the $2.4 million recorded in 3Q 2022. Enerzair and Atectura have emerged as frontrunners in the Canadian asthma market, gaining prominence as essential therapies. The company said it will focus on sales growth and improved gross margins to put it on the path to profitability, with plans to optimize costs further. Valeo Pharma is optimistic about its future prospects and anticipates sustained growth as it continues to serve a vital role in addressing healthcare needs. Contact Details Proactive Investors +1 347-449-0879

September 15, 2023 01:03 PM Eastern Daylight Time

Article thumbnail News Release

CareRX Corporation new CEO sets course for success

CareRx Corporation

CareRx Corporation's new CEO Puneet Khanna joined Steve Darling from Proactive to discuss his new job as CEO. Khanna assumed the role just three months ago and shared his insights on the company's current position and future direction. Khanna brings over 20 years of experience in the pharmacy and senior care sectors to his leadership role at CareRX. Having previously served as the company's Chief Commercial Officer, he is well-versed in the organization's operations and strategic objectives. During the interview, Khanna discussed CareRX's recent second-quarter financial results, emphasizing the company's achievement of organic quarter-over-quarter revenue and adjusted EBITDA growth, which met expectations. These accomplishments are noteworthy, especially in the context of challenges posed by labor market dynamics in the healthcare sector over the past year. Khanna outlined the company's ongoing focus on implementing a comprehensive technology and operational process optimization program. This initiative is expected to yield cost savings and enhance productivity, aligning with CareRX's commitment to delivering high-quality care while remaining operationally efficient. With Khanna's extensive industry experience and the company's dedication to optimizing its operations, CareRX is well-positioned to continue providing vital services in the senior care and pharmacy sectors. As the new CEO, Khanna's vision for the organization's future is anticipated to drive further growth and success. Contact Details Proactive Investors +1 604-688-8158

September 14, 2023 01:18 PM Eastern Daylight Time

Article thumbnail News Release

Align Surgical Associates Welcomes Reconstructive Plastic Surgeon to Burgeoning Gender-Affirming Healthcare Practice

Align Surgical Associates

The California-based gender-affirming healthcare provider Align Surgical Associates Inc. (Align Surgical) announced today that Breanna Y. Jedrzejewski, M.D., M.P.H., has joined its practice. Align Surgical is one of the few interdisciplinary surgical practices in the United States that exclusively provides comprehensive gender-affirming care. “Breanna is a tremendous addition to Align Surgical’s roster of gender-affirming surgeons,” said Align Surgical founder Dr. Thomas Satterwhite. “She brings a breadth of experience, intelligence and compassion to her work and enables us to offer our patients a wider range of practitioners to choose from.” Breanna Y. Jedrzejewski, M.D., M.P.H, is a reconstructive plastic surgeon, specializing in gender-affirming surgical procedures for the face, body, chest or “top” and genital or “bottom” areas. Dr. Jedrzejewski received her M.D. from Brown University and holds a Master of Public Health in Global Health from Yale University. She completed her residency in integrated plastic surgery at Oregon Health and Science University, where her training included a high volume and full breadth of gender-affirming surgeries. Dr. Jedrzejewski is based at Align Surgical’s San Francisco office, serving patients from California and across the United States. Recently, Dr. Jedrzejewski was lead author on “Regret After Gender-Affirming Surgery: A Multidisciplinary Approach to a Multifaceted Patient Experience,” published in the July 2023 issue of Journal of Plastic and Reconstructive Surgery. In the study’s cohort of 1,989 patients, only 0.3% requested reversal surgery or transitioned back to their sex assigned at birth. This finding of an extremely low rate of regret is below the 1.0% rate found in a 2021 review of 27 studies that examined rates of regret following gender-affirming surgeries. It is also significantly lower than rates of regret reported for other common surgeries, such as total knee replacement ( 10%), hip replacement (3%) and numerous cosmetic procedures such as rhinoplasty (9%), breast augmentation (3%) and liposuction (13%), as reported by Statista. Dr. Jedrzejewski’s research also identified that providing a care environment that “welcomes and normalizes authentic expression of gender identity, affirms surgical goals without judgment, and destigmatizes the role of mental health in the surgical process [is] foundational to mitigating the occurrence of any form of regret.” “I am thrilled to have found a practice that is as committed to providing a respectful and safe environment for patients as it is to advancing the field of gender-affirming healthcare through ongoing research,” said Dr. Jedrzejewski. “From the beginning, it was clear to me that Align Surgical shares my approach to the practice of medicine, which is to engage with each patient as a whole and unique person.” Align Surgical’s Commitment to Research and Surgical Innovations Align Surgical is distinguished among private surgical practices in having a foundational commitment to research and training, which typically only occur at large teaching hospitals. Its surgeons actively initiate and participate in ongoing research with academic and peer organizations, such as Stanford University Medical Center and World Professional Association for Transgender Health ( WPATH ), to improve outcomes and advance the field of gender-affirming healthcare. Align Surgical is an official rotation site for Stanford’s plastic surgery residents as they receive training in gender-affirming care. Align Surgical is also one of the only private interdisciplinary surgical practices in the United States that is 100% focused on gender-affirming surgery. While the majority of its patients reside in California, nearly 30% of Align Surgical’s patient base comes to the practice from 48 other states and outside the U.S. Initial consultations are tailored to every individual, whether they are transgender, nonbinary or gender-diverse. Align Surgical’s roster of plastic surgeons and reconstructive urologists offer the full array of gender-affirming procedures, including facial feminization and masculinization; chest or “top” surgeries such as mastectomy or breast augmentation; body contouring; and many forms of genital or “bottom” surgery, such as phalloplasty, metoidioplasty, vaginoplasty and more. Since founding the practice, the surgeons at Align Surgical have been at the forefront of developments in surgical technique and practices to improve patient outcomes. Whether it is addressing patient-focused needs such as finding a better solution for post-vaginoplasty dilation; questioning existing and pervasive practices such as withholding hormone therapy prior to surgery; or examining access to care by studying what operations surgeons in the U.S. are willing to perform for patients, the surgeons at Align Surgical are always seeking to contribute to the body of scientific knowledge. Their priority is always to improve patient outcomes and deliver the best care possible. “The field of gender-affirming healthcare – and surgery specifically – is one of the great new frontiers of medicine,” added Dr. Satterwhite. “As societal acceptance of transgender identities grows, our ability to expand access and improve outcomes for patients grows along with it. This is why I went into medicine: to deliver life-saving and life-affirming care to those who need it most.” * * * About Align Surgical Associates Align Surgical Associates was founded in 2018 with the mission of providing gender-affirming surgery to the transgender, non-binary and gender-diverse community with excellence, compassion and the belief that all people deserve to experience the freedom of living as their true selves. Align Surgical’s surgeons in San Francisco and Los Angeles provide the full range of facial, body contouring, top and bottom surgeries and share a commitment to advancing innovation and research in their specialty fields. More information at Media, please note: Visual assets, including photos and video, are available. To request an interview with experts from Align Surgical Associates, please contact Andie Davis at 415.766.8355 or ### Contact Details Landis Communications Inc. Andie Davis +1 415-766-8355 Company Website

September 14, 2023 08:31 AM Pacific Daylight Time

1 ... 34567 ... 219